Clinical trial · Interventional
Lean Body Mass in Head and Neck Cancer Patients During Cisplatin-based Chemoradiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to investigate the changes in body composition in head and neck cancer patients during treatment. The main questions it aims to answer are: What is the rate of lean body mass loss and how is it associated with changes in muscle strength and functional performance? Is the lean body mass loss impacted by adding chemotherapy to the radiation treatment? Participants will be asked to undergo five body composition scans during treatment and undergo tests for muscle strength and functional performance before and after treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Body Composition Changes | — | UNRESOLVED | — |
| Head and Neck Cancer Patients | Head and Neck Neoplasm | PROBABILISTIC | 0.70 |
| Lean Body Mass | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DXA scan | Diagnostic Test | — | UNRESOLVED |
| Physical testing | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- DXA scans and physical tests
- description
- All patients are allocated to this arm and will undergod DXA scans and physical testing in addition to usual care/treatment
- interventionNames
- Diagnostic Test: DXA scan
- Behavioral: Physical testing
Primary outcomes (1)
- measure
- Lean body mass
- timeFrame
- Bi-weekly from treatment start to two weeks post treatment (5 scans in total)
- description
- Lean body mass in kg determined by DXA scans
Secondary outcomes (1)
- measure
- Fat mass
- timeFrame
- Bi-weekly from treatment start to two weeks post treatment (5 scans in total)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven squamous cell carcinoma of the larynx, pharynx, or oral cavity * Prescribed to radical or post-operative radiotherapy of at least 60 Gy with or without concomitant chemotherapy Exclusion Criteria: * Palliative radiation or participation in competing research protocols
References
Publications (1)
- DERIVEDLonbro S, Gam S, Hermann AP, Hansen CR, Johansen J. Accelerated loss of lean body mass in head and neck cancer patients during cisplatin-based chemoradiation. Acta Oncol. 2023 Nov;62(11):1403-1411. doi: 10.1080/0284186X.2023.2245558. Epub 2023 Aug 17. PMID 37589161